High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients being null responders to prior dual therapy with peginterferon alpha and ribavirin – a proof-of-concept trial on antiviral efficacy and safety

Trial Profile

High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients being null responders to prior dual therapy with peginterferon alpha and ribavirin – a proof-of-concept trial on antiviral efficacy and safety

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Silibinin (Primary) ; Peginterferon alfa; Ribavirin; Telaprevir
  • Indications Hepatitis C
  • Focus Proof of concept; Therapeutic Use
  • Acronyms HISTORY
  • Most Recent Events

    • 07 Feb 2015 Status changed from recruiting to completed, according to European Clinical Trials Database record.
    • 22 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top